What are the drug interactions and clinical considerations when using adalimumab, colchicine, deflazacort, epratuzumab, telmisartan, and naproxen together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Drug Interaction Analysis: Adalimumab, Colchicine, Deflazacort, Apremilast, Telmisartan, and Naproxen

This combination requires careful monitoring for colchicine toxicity, particularly muscle-related adverse effects, gastrointestinal complications, and infection risk, with mandatory dose adjustments for colchicine when used with deflazacort.

Critical Interactions Requiring Immediate Action

Colchicine + Deflazacort (Corticosteroid): HIGH RISK

Reduce colchicine dose by two-thirds (to approximately 0.3-0.6 mg daily) when coadministered with deflazacort 1. Deflazacort is metabolized by CYP3A4 2, creating a competitive substrate interaction with colchicine that can increase colchicine blood levels by 200-300% 3. This combination has resulted in documented cases of myopathy, rhabdomyolysis, multiorgan failure, and death 1.

  • Monitoring requirements: Weekly assessment for muscle pain, weakness, or cramping during the first month, then monthly 1
  • Warning signs of toxicity: Abdominal cramping, vomiting, diarrhea (first sign—reduce dose immediately), muscle weakness, or easy bruising 3, 4
  • Fatal progression: Gastrointestinal symptoms → multiorgan failure (24-72 hours) → bone marrow suppression, renal failure, arrhythmias 3

Colchicine + Naproxen (NSAID): MODERATE-HIGH RISK

Monitor closely for synergistic gastrointestinal and muscle toxicity 5, 3. While NSAIDs like naproxen are recommended first-line agents for gout flares 5, 6, their combination with colchicine increases risk through:

  • Pharmacodynamic interaction: Both independently cause gastrointestinal toxicity and can precipitate colonic perforation, especially with underlying diverticular disease 7
  • Enhanced myotoxicity: NSAIDs may aggravate colchicine-induced muscle damage 8
  • Renal effects: Combined nephrotoxicity risk, particularly in elderly patients 5

Clinical approach: Use proton pump inhibitors when combining colchicine with naproxen 5. Avoid this combination in patients with severe renal impairment (CrCl <30 mL/min) 5.

Adalimumab + Deflazacort: INFECTION RISK

Screen for active infection before initiating or continuing this combination 2. Both agents cause immunosuppression:

  • Deflazacort: Causes dose-dependent immunosuppression, increases infection risk, and may mask signs of infection 2
  • Adalimumab: TNF-alpha inhibitor with known infection risk including tuberculosis reactivation
  • Combined effect: Substantially elevated risk of serious bacterial, viral, and fungal infections

Required monitoring: Complete blood count every 4-8 weeks, immediate evaluation for fever or infection symptoms 2.

Moderate-Risk Interactions

Adalimumab + Naproxen

This combination is commonly used and generally safe 9, though vigilance is needed for:

  • Gastrointestinal events: NSAIDs increase GI bleeding risk; use PPI prophylaxis
  • Infusion reactions: Monitor for hypersensitivity, particularly in adults ≥18 years 9
  • Joint swelling paradox: Male patients show higher incidence of joint swelling with TNF-inhibitor + NSAID combinations 9

Telmisartan + Naproxen

NSAIDs reduce the antihypertensive efficacy of angiotensin receptor blockers by 10-20 mmHg 8.

Management algorithm:

  1. Measure blood pressure weekly for first month after adding naproxen
  2. If BP rises >10/5 mmHg above target, increase telmisartan dose or add second antihypertensive
  3. Consider alternative analgesics (acetaminophen, topical NSAIDs) if BP control becomes problematic
  4. Monitor serum creatinine and potassium monthly—combined use increases hyperkalemia risk 8

Telmisartan + Deflazacort

Corticosteroids antagonize antihypertensive effects and cause sodium retention 2. Expect 5-15 mmHg increase in blood pressure with deflazacort initiation. Increase telmisartan dose preemptively if starting deflazacort at doses >0.9 mg/kg/day 2.

Low-Risk Interactions

Adalimumab + Colchicine

No significant pharmacokinetic interaction. Both can be used together safely for conditions like Behçet's disease or refractory gout 5.

Adalimumab + Telmisartan

No direct interaction. Continue standard monitoring for both agents 10.

Apremilast (Note: Question lists "Eprimilast" but likely refers to Apremilast)

No significant interactions identified with this combination. Apremilast is not a CYP3A4 inhibitor and does not interact with colchicine metabolism.

Renal Impairment Considerations

If creatinine clearance <60 mL/min, implement these mandatory adjustments:

  • Colchicine: Reduce to 0.3 mg daily for prophylaxis; avoid if CrCl <30 mL/min when combined with CYP3A4 substrates 5, 1, 5, 4
  • Naproxen: Avoid if CrCl <30 mL/min 5
  • Telmisartan: Monitor closely; dose adjustment usually not required but increased hyperkalemia risk 10
  • Deflazacort: No specific renal dose adjustment, but increased toxicity risk 2

Hepatic Impairment

Colchicine elimination half-life increases up to sevenfold in liver cirrhosis 3. Reduce colchicine dose by 50% in moderate hepatic impairment; contraindicated in severe hepatic impairment when combined with CYP3A4 substrates 4.

Practical Monitoring Protocol

Week 1-4:

  • Assess for diarrhea, abdominal pain, muscle symptoms (weekly)
  • Check blood pressure (weekly if on telmisartan + naproxen or deflazacort)
  • Evaluate for infection signs (any fever requires immediate assessment)

Month 2-6:

  • CBC, CRP, creatinine, potassium (monthly)
  • Blood pressure (every 2 weeks)
  • Muscle symptoms assessment (monthly)

Beyond 6 months:

  • CBC, metabolic panel (every 3 months)
  • Blood pressure (monthly)
  • Clinical assessment (every 3 months)

Common Pitfalls to Avoid

  1. Failing to reduce colchicine dose with deflazacort: This is the single most dangerous oversight—always reduce to one-third of standard dose 1
  2. Ignoring diarrhea as first sign of colchicine toxicity: Diarrhea mandates immediate dose reduction, not symptomatic treatment 3, 4
  3. Assuming all corticosteroids interact equally: Deflazacort specifically requires colchicine dose adjustment due to CYP3A4 metabolism 2
  4. Overlooking blood pressure changes: NSAIDs and corticosteroids both antagonize antihypertensives—proactive monitoring prevents treatment failure 10, 8
  5. Missing occult infection: Deflazacort + adalimumab masks typical infection symptoms; maintain high index of suspicion 2

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.